Guardant Health, Inc. (NASDAQ:GH) Receives $37.70 Average Price Target from Analysts

Guardant Health, Inc. (NASDAQ:GH) has been assigned a consensus rating of “Moderate Buy” from the twelve research firms that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $35.78.

A number of analysts have recently issued reports on the stock. Canaccord Genuity Group cut their price target on shares of Guardant Health from $45.00 to $30.00 and set a “buy” rating for the company in a report on Monday, April 29th. The Goldman Sachs Group cut their price target on shares of Guardant Health from $32.00 to $28.00 and set a “buy” rating for the company in a report on Monday, April 15th. Piper Sandler cut their price target on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating for the company in a report on Monday, February 26th. Guggenheim restated a “neutral” rating on shares of Guardant Health in a report on Friday, April 5th. Finally, Craig Hallum initiated coverage on shares of Guardant Health in a report on Wednesday, April 24th. They issued a “buy” rating and a $28.00 target price for the company.

Guardant Health Trading Up 4.3 %

GH opened at $19.44 on Friday. The company has a debt-to-equity ratio of 7.18, a current ratio of 6.54 and a quick ratio of 6.24. The company’s 50 day simple moving average is $18.36 and its two-hundred day simple moving average is $22.36. Guardant Health has a 1-year low of $15.81 and a 1-year high of $41.06. The firm has a market capitalization of $2.37 billion, a price-to-earnings ratio of -4.54 and a beta of 0.92.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, February 22nd. The company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.65). The business had revenue of $155.05 million during the quarter, compared to analysts’ expectations of $151.71 million. Guardant Health had a negative return on equity of 301.94% and a negative net margin of 85.02%. Analysts expect that Guardant Health will post -3.49 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Kumud Kalia purchased 2,187 shares of Guardant Health stock in a transaction on Monday, March 18th. The shares were bought at an average price of $17.82 per share, with a total value of $38,972.34. Following the transaction, the insider now directly owns 12,722 shares of the company’s stock, valued at $226,706.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 6.20% of the company’s stock.

Institutional Investors Weigh In On Guardant Health

Large investors have recently modified their holdings of the company. CWM LLC raised its position in shares of Guardant Health by 137.1% during the 3rd quarter. CWM LLC now owns 984 shares of the company’s stock worth $29,000 after acquiring an additional 569 shares in the last quarter. BluePath Capital Management LLC purchased a new position in Guardant Health in the third quarter valued at approximately $35,000. Manchester Capital Management LLC acquired a new stake in Guardant Health during the first quarter worth approximately $57,000. Headlands Technologies LLC lifted its position in shares of Guardant Health by 362.3% during the 4th quarter. Headlands Technologies LLC now owns 2,353 shares of the company’s stock worth $64,000 after buying an additional 1,844 shares during the last quarter. Finally, Van ECK Associates Corp boosted its holdings in shares of Guardant Health by 29.4% in the 4th quarter. Van ECK Associates Corp now owns 2,702 shares of the company’s stock valued at $73,000 after buying an additional 614 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.